Nationwide Trends in Type 1 and Type 2 Diabetes in France (2010–2019): A Population-Based Study Using a Machine Learning Classification Algorithm

Introduction Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with t...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy Vol. 16; no. 10; pp. 1973 - 1991
Main Authors: Fagherazzi, Guy, Serusclat, Pierre, Roux, Barbara, Bretin, Oriane, Casarotto, Emilie, Rabiéga, Pascaline, Rabat, Yolaine, Berteau, Cécile, Pouyet, Antoine, Joubert, Michael
Format: Journal Article
Language:English
Published: Cheshire Springer Healthcare 01.10.2025
Springer
Springer Nature B.V
Subjects:
Adults
Algorithms
Antidiabetics
Cardiology
Chronic illnesses
Classification
Diabetes
Disease
Endocrinology
Epidemiology
Forecasts and trends
Gestational diabetes
Health aspects
Insulin
Internal Medicine
Machine learning
Medicine
Medicine & Public Health
Mortality
Original Research
Population-based studies
Public health
Trends
Type 1 diabetes
Type 2 diabetes
France
Health outcomes
France
Epidemiology
Type 2 diabetes
Machine learning algorithm
Type 1 diabetes
ISSN:1869-6953, 1869-6961
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Introduction Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with type 1 or type 2 diabetes in France from 2010 to 2019. It focused on individuals treated or not with insulin and applied a predictive classification algorithm to accurately distinguish between diabetes types using real-world data. Methods A 10-year retrospective population-based cohort study was conducted from a representative one-tenth sample of the French national healthcare database (i.e. SNDS, Système National des données de Santé), covering nearly the entire French population. Adults (≥ 18 years) affiliated with the general insurance scheme were included. A machine learning algorithm, trained on clinical data from general practitioners, was applied to classify diabetes type. Annual trends in prevalence, incidence, comorbidities, treatments, outpatient care, complications and mortality were assessed. Results Among an extrapolated 5.5 million individuals with diabetes in 2019, 3.5% had type 1 diabetes and 96.5% had type 2 diabetes. The prevalence of type 2 diabetes increased from 6.2% in 2010 to 8.0% in 2019, while type 1 diabetes remained stable. Comorbidity rates were high and increasing in insulin-treated individuals with type 2 diabetes. In 2019, 15.3% of insulin-treated individuals with type 2 diabetes had at least one complication-related hospitalisation. Specialist consultations were underused, especially in type 2 diabetes. The mortality rate in individuals with type 1 diabetes declined from 2.6% to 1.5%, with an increase in mean age at death. Conclusion This national study provides updated insights into diabetes in France and highlights the need to improve access to specialised care and reinforce long-term surveillance strategies.
AbstractList IntroductionDiabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with type 1 or type 2 diabetes in France from 2010 to 2019. It focused on individuals treated or not with insulin and applied a predictive classification algorithm to accurately distinguish between diabetes types using real-world data.MethodsA 10-year retrospective population-based cohort study was conducted from a representative one-tenth sample of the French national healthcare database (i.e. SNDS, Système National des données de Santé), covering nearly the entire French population. Adults (≥ 18 years) affiliated with the general insurance scheme were included. A machine learning algorithm, trained on clinical data from general practitioners, was applied to classify diabetes type. Annual trends in prevalence, incidence, comorbidities, treatments, outpatient care, complications and mortality were assessed.ResultsAmong an extrapolated 5.5 million individuals with diabetes in 2019, 3.5% had type 1 diabetes and 96.5% had type 2 diabetes. The prevalence of type 2 diabetes increased from 6.2% in 2010 to 8.0% in 2019, while type 1 diabetes remained stable. Comorbidity rates were high and increasing in insulin-treated individuals with type 2 diabetes. In 2019, 15.3% of insulin-treated individuals with type 2 diabetes had at least one complication-related hospitalisation. Specialist consultations were underused, especially in type 2 diabetes. The mortality rate in individuals with type 1 diabetes declined from 2.6% to 1.5%, with an increase in mean age at death.ConclusionThis national study provides updated insights into diabetes in France and highlights the need to improve access to specialised care and reinforce long-term surveillance strategies.
Introduction Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with type 1 or type 2 diabetes in France from 2010 to 2019. It focused on individuals treated or not with insulin and applied a predictive classification algorithm to accurately distinguish between diabetes types using real-world data. Methods A 10-year retrospective population-based cohort study was conducted from a representative one-tenth sample of the French national healthcare database (i.e. SNDS, Système National des données de Santé), covering nearly the entire French population. Adults ([greater than or equal to] 18 years) affiliated with the general insurance scheme were included. A machine learning algorithm, trained on clinical data from general practitioners, was applied to classify diabetes type. Annual trends in prevalence, incidence, comorbidities, treatments, outpatient care, complications and mortality were assessed. Results Among an extrapolated 5.5 million individuals with diabetes in 2019, 3.5% had type 1 diabetes and 96.5% had type 2 diabetes. The prevalence of type 2 diabetes increased from 6.2% in 2010 to 8.0% in 2019, while type 1 diabetes remained stable. Comorbidity rates were high and increasing in insulin-treated individuals with type 2 diabetes. In 2019, 15.3% of insulin-treated individuals with type 2 diabetes had at least one complication-related hospitalisation. Specialist consultations were underused, especially in type 2 diabetes. The mortality rate in individuals with type 1 diabetes declined from 2.6% to 1.5%, with an increase in mean age at death. Conclusion This national study provides updated insights into diabetes in France and highlights the need to improve access to specialised care and reinforce long-term surveillance strategies.
Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with type 1 or type 2 diabetes in France from 2010 to 2019. It focused on individuals treated or not with insulin and applied a predictive classification algorithm to accurately distinguish between diabetes types using real-world data.INTRODUCTIONDiabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with type 1 or type 2 diabetes in France from 2010 to 2019. It focused on individuals treated or not with insulin and applied a predictive classification algorithm to accurately distinguish between diabetes types using real-world data.A 10-year retrospective population-based cohort study was conducted from a representative one-tenth sample of the French national healthcare database (i.e. SNDS, Système National des données de Santé), covering nearly the entire French population. Adults (≥ 18 years) affiliated with the general insurance scheme were included. A machine learning algorithm, trained on clinical data from general practitioners, was applied to classify diabetes type. Annual trends in prevalence, incidence, comorbidities, treatments, outpatient care, complications and mortality were assessed.METHODSA 10-year retrospective population-based cohort study was conducted from a representative one-tenth sample of the French national healthcare database (i.e. SNDS, Système National des données de Santé), covering nearly the entire French population. Adults (≥ 18 years) affiliated with the general insurance scheme were included. A machine learning algorithm, trained on clinical data from general practitioners, was applied to classify diabetes type. Annual trends in prevalence, incidence, comorbidities, treatments, outpatient care, complications and mortality were assessed.Among an extrapolated 5.5 million individuals with diabetes in 2019, 3.5% had type 1 diabetes and 96.5% had type 2 diabetes. The prevalence of type 2 diabetes increased from 6.2% in 2010 to 8.0% in 2019, while type 1 diabetes remained stable. Comorbidity rates were high and increasing in insulin-treated individuals with type 2 diabetes. In 2019, 15.3% of insulin-treated individuals with type 2 diabetes had at least one complication-related hospitalisation. Specialist consultations were underused, especially in type 2 diabetes. The mortality rate in individuals with type 1 diabetes declined from 2.6% to 1.5%, with an increase in mean age at death.RESULTSAmong an extrapolated 5.5 million individuals with diabetes in 2019, 3.5% had type 1 diabetes and 96.5% had type 2 diabetes. The prevalence of type 2 diabetes increased from 6.2% in 2010 to 8.0% in 2019, while type 1 diabetes remained stable. Comorbidity rates were high and increasing in insulin-treated individuals with type 2 diabetes. In 2019, 15.3% of insulin-treated individuals with type 2 diabetes had at least one complication-related hospitalisation. Specialist consultations were underused, especially in type 2 diabetes. The mortality rate in individuals with type 1 diabetes declined from 2.6% to 1.5%, with an increase in mean age at death.This national study provides updated insights into diabetes in France and highlights the need to improve access to specialised care and reinforce long-term surveillance strategies.CONCLUSIONThis national study provides updated insights into diabetes in France and highlights the need to improve access to specialised care and reinforce long-term surveillance strategies.
Introduction Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with type 1 or type 2 diabetes in France from 2010 to 2019. It focused on individuals treated or not with insulin and applied a predictive classification algorithm to accurately distinguish between diabetes types using real-world data. Methods A 10-year retrospective population-based cohort study was conducted from a representative one-tenth sample of the French national healthcare database (i.e. SNDS, Système National des données de Santé), covering nearly the entire French population. Adults (≥ 18 years) affiliated with the general insurance scheme were included. A machine learning algorithm, trained on clinical data from general practitioners, was applied to classify diabetes type. Annual trends in prevalence, incidence, comorbidities, treatments, outpatient care, complications and mortality were assessed. Results Among an extrapolated 5.5 million individuals with diabetes in 2019, 3.5% had type 1 diabetes and 96.5% had type 2 diabetes. The prevalence of type 2 diabetes increased from 6.2% in 2010 to 8.0% in 2019, while type 1 diabetes remained stable. Comorbidity rates were high and increasing in insulin-treated individuals with type 2 diabetes. In 2019, 15.3% of insulin-treated individuals with type 2 diabetes had at least one complication-related hospitalisation. Specialist consultations were underused, especially in type 2 diabetes. The mortality rate in individuals with type 1 diabetes declined from 2.6% to 1.5%, with an increase in mean age at death. Conclusion This national study provides updated insights into diabetes in France and highlights the need to improve access to specialised care and reinforce long-term surveillance strategies.
Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with type 1 or type 2 diabetes in France from 2010 to 2019. It focused on individuals treated or not with insulin and applied a predictive classification algorithm to accurately distinguish between diabetes types using real-world data. A 10-year retrospective population-based cohort study was conducted from a representative one-tenth sample of the French national healthcare database (i.e. SNDS, Système National des données de Santé), covering nearly the entire French population. Adults ([greater than or equal to] 18 years) affiliated with the general insurance scheme were included. A machine learning algorithm, trained on clinical data from general practitioners, was applied to classify diabetes type. Annual trends in prevalence, incidence, comorbidities, treatments, outpatient care, complications and mortality were assessed. Among an extrapolated 5.5 million individuals with diabetes in 2019, 3.5% had type 1 diabetes and 96.5% had type 2 diabetes. The prevalence of type 2 diabetes increased from 6.2% in 2010 to 8.0% in 2019, while type 1 diabetes remained stable. Comorbidity rates were high and increasing in insulin-treated individuals with type 2 diabetes. In 2019, 15.3% of insulin-treated individuals with type 2 diabetes had at least one complication-related hospitalisation. Specialist consultations were underused, especially in type 2 diabetes. The mortality rate in individuals with type 1 diabetes declined from 2.6% to 1.5%, with an increase in mean age at death. This national study provides updated insights into diabetes in France and highlights the need to improve access to specialised care and reinforce long-term surveillance strategies.
Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain limited. This study aimed to describe trends in the epidemiology, care pathways and health outcomes of adult individuals living with type 1 or type 2 diabetes in France from 2010 to 2019. It focused on individuals treated or not with insulin and applied a predictive classification algorithm to accurately distinguish between diabetes types using real-world data. A 10-year retrospective population-based cohort study was conducted from a representative one-tenth sample of the French national healthcare database (i.e. SNDS, Système National des données de Santé), covering nearly the entire French population. Adults (≥ 18 years) affiliated with the general insurance scheme were included. A machine learning algorithm, trained on clinical data from general practitioners, was applied to classify diabetes type. Annual trends in prevalence, incidence, comorbidities, treatments, outpatient care, complications and mortality were assessed. Among an extrapolated 5.5 million individuals with diabetes in 2019, 3.5% had type 1 diabetes and 96.5% had type 2 diabetes. The prevalence of type 2 diabetes increased from 6.2% in 2010 to 8.0% in 2019, while type 1 diabetes remained stable. Comorbidity rates were high and increasing in insulin-treated individuals with type 2 diabetes. In 2019, 15.3% of insulin-treated individuals with type 2 diabetes had at least one complication-related hospitalisation. Specialist consultations were underused, especially in type 2 diabetes. The mortality rate in individuals with type 1 diabetes declined from 2.6% to 1.5%, with an increase in mean age at death. This national study provides updated insights into diabetes in France and highlights the need to improve access to specialised care and reinforce long-term surveillance strategies.
Audience Academic
Author Casarotto, Emilie
Pouyet, Antoine
Rabat, Yolaine
Rabiéga, Pascaline
Bretin, Oriane
Roux, Barbara
Berteau, Cécile
Fagherazzi, Guy
Serusclat, Pierre
Joubert, Michael
Author_xml – sequence: 1
  givenname: Guy
  orcidid: 0000-0001-5033-5966
  surname: Fagherazzi
  fullname: Fagherazzi, Guy
  organization: Deep Digital Phenotyping Research Unit, Department of Precision Health, Luxembourg Institute of Health
– sequence: 2
  givenname: Pierre
  surname: Serusclat
  fullname: Serusclat, Pierre
  organization: Endocrinology, Diabetology and Nutrition, Clinique Portes du Sud
– sequence: 3
  givenname: Barbara
  orcidid: 0000-0002-0303-1246
  surname: Roux
  fullname: Roux, Barbara
  organization: IQVIA, RWS
– sequence: 4
  givenname: Oriane
  surname: Bretin
  fullname: Bretin, Oriane
  organization: IQVIA, RWS
– sequence: 5
  givenname: Emilie
  orcidid: 0000-0003-1891-417X
  surname: Casarotto
  fullname: Casarotto, Emilie
  organization: IQVIA, RWS
– sequence: 6
  givenname: Pascaline
  surname: Rabiéga
  fullname: Rabiéga, Pascaline
  organization: IQVIA, RWS
– sequence: 7
  givenname: Yolaine
  orcidid: 0000-0002-1244-0535
  surname: Rabat
  fullname: Rabat, Yolaine
  organization: IQVIA, RWS
– sequence: 8
  givenname: Cécile
  surname: Berteau
  fullname: Berteau, Cécile
  organization: Roche Diagnostics
– sequence: 9
  givenname: Antoine
  surname: Pouyet
  fullname: Pouyet, Antoine
  organization: Timkl
– sequence: 10
  givenname: Michael
  orcidid: 0000-0002-8731-7355
  surname: Joubert
  fullname: Joubert, Michael
  email: joubert-m@chu-caen.fr
  organization: Diabetes Care Unit, Caen University Hospital, UNICAEN
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40900398$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1uEzEQx1eoiJbSF-CALHEphy1je7_MLQRKkcKHRHq2HHucutp4g70rlBvvgLjzLDwKT1JvElqBEPZhxuPfjMea_8PswHces-wxhTMKUD-PlHOAHFiZA60bmsO97Ig2lcgrUdGDW7_kh9lJjNeQFhdCUPogOyxAjKfmKPv-XvWu81-cQTIP6E0kzpP5Zo0_f1CivNn7jLxyaoE9bu_Pg_IaySkDCr--fktGPHtBJuRjtx7abcH8pYpoyKd-MBtyGZ1fEkXeKX3lPJIZquDH0LRVMTrr9DaHTNplF1x_tXqU3beqjXiyt8fZ5fnr-fQin31483Y6meW64KLPFce6xKau1EJbY4VVVlta1bRBhkVdC2CUG1EsUCNwNEwZDaa0oqTCqILx4-x0V3cdus8Dxl6uXNTYtspjN0TJWVExwRiUCX36F3rdDcGn7hJVlo1ooIY7aqlalM7brg9Kj0XlpCnrEkQBdaLO_kGlbXDldJqzdSn-R8KT_ePDYoVGroNbqbCRv-eYALYDdOhiDGhvEQpy1Ivc6UUmvcitXuTYLN8lxQT7JYa7L_0n6wbSnsD0
Cites_doi 10.1016/j.diabet.2019.12.006
10.1016/S2213-8587(20)30402-2
10.1136/bmj-2023-078432
10.1016/S0140-6736(23)01301-6
10.1016/j.deman.2023.100137
10.1038/s41574-022-00690-7
10.1177/2047487319878371
10.1016/j.diabet.2024.101509
10.1016/j.diabet.2025.101615
10.1007/s41669-017-0050-3
10.1002/pds.4233
10.1186/s12916-024-03343-w
10.1016/j.respe.2017.05.004
10.1016/j.eclinm.2023.101860
10.1155/2018/3086167
10.1016/S0140-6736(13)60595-4
10.2337/dc21-1752
10.1089/dia.2015.0224
10.1016/j.ando.2022.05.005
10.1016/S0140-6736(18)31506-X
10.3389/fendo.2023.1307432
ContentType Journal Article
Copyright The Author(s) 2025
2025. The Author(s).
COPYRIGHT 2025 Springer
The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2025
– notice: 2025. The Author(s).
– notice: COPYRIGHT 2025 Springer
– notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
K9.
NAPCQ
7X8
DOI 10.1007/s13300-025-01781-0
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)

MEDLINE - Academic


PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1869-6961
EndPage 1991
ExternalDocumentID A857509407
40900398
10_1007_s13300_025_01781_0
Genre Journal Article
GeographicLocations France
GeographicLocations_xml – name: France
GrantInformation_xml – fundername: Roche Diabetes Care (FR)
GroupedDBID ---
0R~
2VQ
4.4
40G
53G
5VS
7RV
7X7
8AO
8C1
8FI
8FJ
AAKDD
AAKKN
AAYZH
ABDBF
ABEEZ
ABUWG
ACACY
ACGFS
ACIHN
ACMJI
ACUHS
ACULB
ADBBV
ADRAZ
AEAQA
AFGXO
AFKRA
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
AZQEC
BAPOH
BAWUL
BCNDV
BENPR
BKEYQ
BKNYI
BPHCQ
BVXVI
C24
C6C
CCPQU
DIK
EBS
EJD
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
HZ~
IAO
IHR
ITC
K9-
KQ8
LGEZI
LOTEE
M0R
M48
M~E
NADUK
NAPCQ
NXXTH
O5R
O5S
O9-
OK1
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PUEGO
RNS
RPM
SISQX
SMD
SOJ
U2A
UKHRP
~JE
AAYXX
AFFHD
CITATION
EIHBH
NPM
K9.
7X8
ID FETCH-LOGICAL-c439t-a3e75e876abcfdf9fafcf16718e2e47790213d94bece03ed2adc0d5f9519da423
IEDL.DBID C24
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001562881700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1869-6953
IngestDate Thu Oct 02 21:36:18 EDT 2025
Fri Nov 07 23:28:53 EST 2025
Sat Nov 29 13:46:05 EST 2025
Mon Nov 24 15:41:30 EST 2025
Tue Sep 30 01:30:56 EDT 2025
Sat Nov 29 07:24:23 EST 2025
Sat Sep 27 01:12:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Health outcomes
France
Epidemiology
Type 2 diabetes
Machine learning algorithm
Type 1 diabetes
Language English
License 2025. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c439t-a3e75e876abcfdf9fafcf16718e2e47790213d94bece03ed2adc0d5f9519da423
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-5033-5966
0000-0002-0303-1246
0000-0002-1244-0535
0000-0003-1891-417X
0000-0002-8731-7355
OpenAccessLink https://link.springer.com/10.1007/s13300-025-01781-0
PMID 40900398
PQID 3255898070
PQPubID 2034778
PageCount 19
ParticipantIDs proquest_miscellaneous_3246292205
proquest_journals_3255898070
gale_infotracmisc_A857509407
gale_infotracacademiconefile_A857509407
pubmed_primary_40900398
crossref_primary_10_1007_s13300_025_01781_0
springer_journals_10_1007_s13300_025_01781_0
PublicationCentury 2000
PublicationDate 2025-10-01
PublicationDateYYYYMMDD 2025-10-01
PublicationDate_xml – month: 10
  year: 2025
  text: 2025-10-01
  day: 01
PublicationDecade 2020
PublicationPlace Cheshire
PublicationPlace_xml – name: Cheshire
– name: United States
– name: Tarporley
PublicationSubtitle Research, treatment and education of diabetes and related disorders
PublicationTitle Diabetes therapy
PublicationTitleAbbrev Diabetes Ther
PublicationTitleAlternate Diabetes Ther
PublicationYear 2025
Publisher Springer Healthcare
Springer
Springer Nature B.V
Publisher_xml – name: Springer Healthcare
– name: Springer
– name: Springer Nature B.V
References 1781_CR21
S Fuentes (1781_CR12) 2023; 10
1781_CR22
B Wang (1781_CR32) 2024; 22
S Roze (1781_CR31) 2016; 18
D Liang (1781_CR29) 2023; 14
Y Reznik (1781_CR11) 2023; 84
J Bezin (1781_CR8) 2017; 26
JL Harding (1781_CR7) 2022; 45
M Guion (1781_CR14) 2024; 50
B Charbonnel (1781_CR33) 2018; 2
1781_CR28
DJ Magliano (1781_CR1) 2021; 9
1781_CR25
1781_CR23
S Fosse-Edorh (1781_CR15) 2025; 51
1781_CR10
K Yang (1781_CR30) 2024; 385
A Rawshani (1781_CR26) 2018; 392
RT Gansevoort (1781_CR20) 2013; 382
SR Chowdhury (1781_CR24) 2023; 57
P Tuppin (1781_CR16) 2017; 65
1781_CR9
S Fosse-Edorh (1781_CR13) 2022; 22
S Fuentes (1781_CR19) 2020; 46
E Dal Canto (1781_CR27) 2019; 26
1781_CR18
1781_CR6
1781_CR3
1781_CR17
1781_CR36
1781_CR2
D Tomic (1781_CR5) 2022; 18
1781_CR34
K Papatheodorou (1781_CR4) 2018; 2018
1781_CR35
References_xml – volume: 46
  start-page: 472
  issue: 6
  year: 2020
  ident: 1781_CR19
  publication-title: Diabetes Metab
  doi: 10.1016/j.diabet.2019.12.006
– ident: 1781_CR2
– volume: 9
  start-page: 203
  issue: 4
  year: 2021
  ident: 1781_CR1
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(20)30402-2
– volume: 385
  year: 2024
  ident: 1781_CR30
  publication-title: BMJ
  doi: 10.1136/bmj-2023-078432
– ident: 1781_CR6
  doi: 10.1016/S0140-6736(23)01301-6
– volume: 10
  year: 2023
  ident: 1781_CR12
  publication-title: Diabetes Epidemiol Manag
  doi: 10.1016/j.deman.2023.100137
– ident: 1781_CR25
– volume: 18
  start-page: 525
  issue: 9
  year: 2022
  ident: 1781_CR5
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/s41574-022-00690-7
– ident: 1781_CR23
– volume: 26
  start-page: 25
  issue: 2_suppl
  year: 2019
  ident: 1781_CR27
  publication-title: Eur J Prev Cardiol
  doi: 10.1177/2047487319878371
– ident: 1781_CR21
– volume: 50
  issue: 2
  year: 2024
  ident: 1781_CR14
  publication-title: Diabetes Metab
  doi: 10.1016/j.diabet.2024.101509
– volume: 51
  issue: 2
  year: 2025
  ident: 1781_CR15
  publication-title: Diabetes Metab
  doi: 10.1016/j.diabet.2025.101615
– volume: 2
  start-page: 209
  issue: 2
  year: 2018
  ident: 1781_CR33
  publication-title: Pharmacoecon Open
  doi: 10.1007/s41669-017-0050-3
– volume: 26
  start-page: 954
  issue: 8
  year: 2017
  ident: 1781_CR8
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.4233
– volume: 22
  start-page: 114
  issue: 1
  year: 2024
  ident: 1781_CR32
  publication-title: BMC Med
  doi: 10.1186/s12916-024-03343-w
– ident: 1781_CR35
– volume: 65
  start-page: S149
  year: 2017
  ident: 1781_CR16
  publication-title: Rev Epidemiol Sante Publique
  doi: 10.1016/j.respe.2017.05.004
– volume: 57
  year: 2023
  ident: 1781_CR24
  publication-title: eClinicalMedicine
  doi: 10.1016/j.eclinm.2023.101860
– volume: 2018
  start-page: 3086167
  year: 2018
  ident: 1781_CR4
  publication-title: J Diabetes Res
  doi: 10.1155/2018/3086167
– volume: 382
  start-page: 339
  issue: 9889
  year: 2013
  ident: 1781_CR20
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)60595-4
– volume: 45
  start-page: 994
  issue: 4
  year: 2022
  ident: 1781_CR7
  publication-title: Diabetes Care
  doi: 10.2337/dc21-1752
– ident: 1781_CR10
– ident: 1781_CR3
– ident: 1781_CR18
– volume: 18
  start-page: 75
  issue: 2
  year: 2016
  ident: 1781_CR31
  publication-title: Diabetes Technol Ther
  doi: 10.1089/dia.2015.0224
– volume: 84
  start-page: 21
  issue: 1
  year: 2023
  ident: 1781_CR11
  publication-title: Ann Endocrinol (Paris)
  doi: 10.1016/j.ando.2022.05.005
– ident: 1781_CR28
– volume: 392
  start-page: 477
  issue: 10146
  year: 2018
  ident: 1781_CR26
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)31506-X
– ident: 1781_CR22
– ident: 1781_CR9
– ident: 1781_CR34
– volume: 22
  start-page: 383
  year: 2022
  ident: 1781_CR13
  publication-title: Bull Epidémiol Hebd
– volume: 14
  start-page: 1307432
  year: 2023
  ident: 1781_CR29
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2023.1307432
– ident: 1781_CR36
– ident: 1781_CR17
SSID ssj0000399911
Score 2.3473577
Snippet Introduction Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use...
Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain...
Introduction Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use...
Diabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use remain...
IntroductionDiabetes represents an increasing public health challenge in France, yet national data distinguishing type 1 from type 2 diabetes and insulin use...
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 1973
SubjectTerms Adults
Algorithms
Antidiabetics
Cardiology
Chronic illnesses
Classification
Diabetes
Disease
Endocrinology
Epidemiology
Forecasts and trends
Gestational diabetes
Health aspects
Insulin
Internal Medicine
Machine learning
Medicine
Medicine & Public Health
Mortality
Original Research
Population-based studies
Public health
Trends
Type 1 diabetes
Type 2 diabetes
Title Nationwide Trends in Type 1 and Type 2 Diabetes in France (2010–2019): A Population-Based Study Using a Machine Learning Classification Algorithm
URI https://link.springer.com/article/10.1007/s13300-025-01781-0
https://www.ncbi.nlm.nih.gov/pubmed/40900398
https://www.proquest.com/docview/3255898070
https://www.proquest.com/docview/3246292205
Volume 16
WOSCitedRecordID wos001562881700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1869-6961
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000399911
  issn: 1869-6953
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAVX
  databaseName: SpringerLink
  customDbUrl:
  eissn: 1869-6961
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000399911
  issn: 1869-6953
  databaseCode: C24
  dateStart: 20100801
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB7RglAv_LcESmUkJEBgKYnzY3NbqlZctuoBpL1ZTuyUlUoW7aYgLqjvUHHnWXgUnoQZx9llKzjAJYlkO3Hs8fxovpkBeBK7WDWlMLySteCZcZZLoyqOkl5alCdVZo0vNlEeHcnJRB2HoLDFgHYfXJKeU6-C3dD0jjmVX6WS8mgEb8DVPJGKgHz7IcbB819BSo-3tGSheKFyEaJl_vyaNYl0mS__JpgueUq9ADq8-X9TvwU3gsLJRj2F3IYrrr0D18fBpX4XvvWZsT9PrWM9QJZNW0bm6Y_vCTOtDc8pC-AZ3-7rcTj2jLzcP88v8Kaev2IjdrysB8Zfo3y0jHCKX5gHJjDDxh666VjI6nrCfE1OQiv5MWx0ejKbT7v3H-7Bu8ODt_tveKjVwGtUaTpuhCtzh6zVVHVjG9WYpm6SAiWfS11GSQ3TRFiVIcm4WDibGlvHNm9QwVPWoE63DZvtrHX3gVllUIeNq6LJ46z2GhQqKiYTNimkkmkEL4b90h_7lBx6lXyZVlrjSmu_0jqO4Cltqabz2s1NbULYAX6LMl_pEZUopSSCZQS7az3xnNXrzQNR6HDOF1qgRYZzQr4ZweNlM40k7FrrZmfUJytSRQHNEez0xLScN1rXRK8ygpcD5axe_vefevBv3R_CVkrE5zGIu7DZzc_cI7hWf-qmi_kebJQTuefPEF7HXw9-AZsJEzc
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VFlEu5dVHSgEjIQGilrJxNhtzWyqqIrqrHorUm-XYTrtSm612UxA3_gPizm_hp_BLmHGcXbaCA5wSyY849ngemm9mAJ7FLpZlT2he5EbwVDvLcy0LjpI-tyhPitRqX2yiNxzmJyfyKASFTVu0e-uS9Jx6HuyGpnfMqfwqlZRHI_gGrFDqFQLy7YUYB89_BSk93tLKM8kz2RUhWubP0yxIpOt8-TfBdM1T6gXQ_p3_W_pdWAsKJ-s3FHIPllx1H24Ngkv9AXxrMmN_GlnHGoAsG1WMzNMf3ztMVza8JyyAZ3y7r8fh2Avycv_88hUf8uVr1mdHs3pg_A3KR8sIp_iZeWAC02zgoZuOhayup8zX5CS0kh_D-uen48moPrtYhw_7b4_3Dnio1cANqjQ118L1ug5Zqy5MaUtZ6tKUnQwln0tcSkkNk46wMkWScbFwNtHWxLZbooInrUadbgOWq3HltoBZqVGHjYus7Map8RoUKio6FbaT5TJPInjVnpe6bFJyqHnyZdpphTut_E6rOILndKSK7ms90UaHsAP8FmW-Un0qUUpJBHsR7Cz0xHtmFptbolDhnk-VQIsM14R8M4Kns2YaSdi1yo2vqE-aJZICmiPYbIhptm60role8wh2W8qZT_73n9r-t-5PYPXgeHCoDt8N3z-E2wkRoscj7sByPblyj-Cm-ViPppPH_ib9AptfFAM
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB6VFlVcKP-EFjASEiCwmo2z2bi3pbACQVd7AKk3y_FPWQmy1TYFceMdUO99Fh6FJ-mM493tVnBAnBLJduKfGc-M5psZgMepS6XvCc2r0giea2d5qWXFUdKXFuVJlVsdik30hsNyf1-OzkXxB7T7zCXZxjRQlqa62T60fnsR-IZmeMqpFCuVl0eD-BKskUeKaHw3xjuEu1iQAhSsrrKQvJBdESNn_vyZJel08Y4-J6QueE2DMBps_P8yrsHVqIiyfks512HF1TdgfS-62m_CSZsx-9vYOtYCZ9m4ZmS2_jrtMF3b-J6xCKoJ7aFOh2NPyfv9-8dPfMhnO6zPRvM6Yfwlyk3LCL_4nQXAAtNsL0A6HYvZXg9YqNVJKKYwhvU_H0ym4-bTl1vwcfD6w-4bHms4cIOqTsO1cL2uwytXV8ZbL732xncKlIguczklO8w6wsocScmlwtlMW5ParkfFT1qNut5tWK0ntbsLzEqNum1aFb6b5iZoVqjA6FzYTlHKMkvg-ezs1GGbqkMtkjLTTivcaRV2WqUJPKHjVcTHzVQbHcMR8F-UEUv1qXQpJRfsJbC11BP5zyw3zwhERf4_UgItNZwT3qcJPJo300jCtNVuckx98iKTFOicwJ2WsObzRqubaLdM4MWMihYf__ui7v1b94ewPno1UO_fDt9twpWM6DDAFLdgtZkeu_tw2XxtxkfTB4GpzgCb0Bzn
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nationwide+Trends+in+Type%C2%A01+and+Type%C2%A02+Diabetes+in+France+%282010%E2%80%932019%29%3A+A+Population-Based+Study+Using+a+Machine+Learning+Classification+Algorithm&rft.jtitle=Diabetes+therapy&rft.au=Fagherazzi%2C+Guy&rft.au=Serusclat%2C+Pierre&rft.au=Roux%2C+Barbara&rft.au=Bretin%2C+Oriane&rft.date=2025-10-01&rft.issn=1869-6953&rft.eissn=1869-6961&rft.volume=16&rft.issue=10&rft.spage=1973&rft.epage=1991&rft_id=info:doi/10.1007%2Fs13300-025-01781-0&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s13300_025_01781_0
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1869-6953&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1869-6953&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1869-6953&client=summon